Abstract:Background Concerns have been raised about the appropriateness of use and safety of beta-blockers (BBs) in patients with heart failure and mildly reduced (HFmrEF) and preserved ejection fraction (HFpEF). However, randomized trial evidence is still lacking. Purpose To perform an observational analysis of the association between BB use and clinical outcomes in a large dataset of patients with HFmrEF and HFpEF. Methods We pooled individual patient data from four large HFmrEF/HFpEF trials (I-Preserve, TOPCAT, PARAGON-HF, and DELIVER). The associations between baseline BB use and outcomes were analyzed. The primary outcome was the composite of cardiovascular death or HF hospitalization. Results Among the 16,951 patients included, the mean left ventricular ejection fraction (LVEF) was 56.8%, and 13,400 (79.1%) had HFpEF (LVEF ≥50%). Overall, 12,812 patients (75.6%) received a BB. The median bisoprolol-equivalent dose of BB was 5.0 (Q1-Q3: 2.5-5.0) mg with BB continuation rates of 95.1% at 1 year and 93.1% at 2 years (in patients who survived more than 1 and 2 years, respectively). Overall, the hazard ratio (HR) for the primary outcome did not differ between BB users and non-users (HR: 0.98 [95% CI: 0.91-1.05]) but among patients with HFmrEF, BB users had a lower HR (0.84 [95% CI 0.71-0.98]), whereas in HFpEF the HR was similar BB users and non-users (0.99 [95% CI 0.92-1.08]). However, after comprehensive adjustment for known prognostic variables, including NT-proBNP, BB use was associated with a better outcome in the overall cohort (HR 0.81 [0.74-0.88]), and this association was maintained across the range of LVEF (Figure 1). In subgroup analyses, the risk of the primary outcome was similar in BB users and non-users with or without a history of myocardial infarction, with or without a history of hypertension, or with or without a baseline heart rate <70 bpm. By contrast, a better outcome with BB use was seen in patients with atrial fibrillation compared to those without atrial fibrillation (Figure 2). Conclusions Although this is an observational analysis of non-randomized treatment, there was no suggestion that BB use was associated with worse HF outcomes even after extensive adjustment for other prognostic variables. Figure Legends Figure 1. Association between beta-blocker use and outcomes across the range of LVEF. Risk in beta-blocker users versus non-users is shown as an adjusted continuous hazard ratio Figure 2. Association between beta-blocker use and non-use in the overall population and clinically relevant patient subgroups, shown as an adjusted hazard ratio (HR). The outcome analyzed was the composite of CV death or HF hospitalization (primary outcome)Figure 1Figure 2

Genome-Wide Association Study of Beta-Blocker Survival Benefit in Black and White Patients with Heart Failure with Reduced Ejection Fraction

Abstract 15985: Comparison of Survival Benefit From Angiotensin Inhibitors in Patients With Heart Failure and Reduced Ejection Fraction by Race and Genomic Ancestry

Survival Association of Angiotensin Inhibitors in Heart Failure With Reduced Ejection Fraction: Comparisons Using Self-Identified Race and Genomic Ancestry

Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade.

Revisiting Race and the Benefit of RAS Blockade in Heart Failure: A Meta-Analysis of Randomized Clinical Trials

Abstract 18410: Prescriptions for and Use of Β-Blocker Following Heart Failure Hospitalization: the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study

Disparity In Beta Blocker Prescription In Heart Failure

Equal Treatment, Unequal Outcomes? Debunking the Racial Disparity in Renin Angiotensin Aldosterone System Inhibitor Associated Reduction in Heart Failure Hospitalizations

Combining Genetic Proxies of Drug Targets and Time-to-event analyses From Longitudinal Observational Data To Identify Target Patient Populations

Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease

Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction

Abstract 11440: Subclinical Cardiovascular and Non-Cardiovascular Risk Factors for Heart Failure with Preserved and Reduced Ejection Fraction in Black Americans: The Jackson Heart Study

Beta blockers are associated with lower all-cause mortality among HFpEF patients

Rationale and Design of the Beta-Blocker in Heart Failure with Normal Left Ventricular Ejection Fraction (Beta-Preserve) Study.

A Multivariable Mendelian Randomization Study of Systolic and Diastolic Blood Pressure, Lipid Profile, and Heart Failure Subtypes

SA15 Clinical Outcomes of Pharmacological Therapies for Heart Failure in Black Vs. White Populations: A Meta-Analysis of Randomized Controlled Trials of Heart Failure Treatment

Race in Heart Failure: A Pooled Participant-Level Analysis of the Global PARADIGM-HF and PARAGON-HF Trials

Multi-trait genome-wide analysis identified novel risk loci and candidate drugs for heart failure

Identifying racial disparities in the management of heart failure with reduced ejection fraction

Pharmacogenomic Effects of β-Blocker Use on Femoral Neck Bone Mineral Density